(TITLE-ABS-KEY (“SGLT2 inhibitors” OR empagliflozin OR dapagliflozin OR canagliflozin OR ertugliflozin) AND TITLE-ABS-KEY (ascites OR “fluid retention” OR “refractory ascites”) AND TITLE-ABS-KEY (cirrhosis OR “hepatic cirrhosis” OR “liver cirrhosis”)). The gene discussed is SLC5A2; the disease is cirrhosis of liver.